Pharmexa reports progress in US breast cancer trial
Preliminary results with HER-2 AutoVac(TM) Protein vaccine are expected before the end of the year
The clinical trial, which takes place at two US breast cancer centres in Cleveland and Pittsburgh, includes 10 patients with breast cancer. The primary objective of the trial is to evaluate the safety of the HER-2 AutoVac(TM) Protein vaccine. In addition, the ability of the vaccine to activate a specific immune response against cancer cells expressing the HER-2 protein will be evaluated.
Recruitment of patients to the trial has now been completed according to schedule and all 10 patients have started treatment. Based on this, Pharmexa expects to be able to announce preliminary data from the trial before the end of the year.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.